New Research on Blood Pressure Medications and Dementia
Study Overview
Recent research published in The Lancet reveals the potential anti-dementia effects of commonly prescribed blood pressure medications. Released in May 2024, the study examined 34 years of Dutch medical records, confirming that certain antihypertensive drugs can reduce the risk of dementia by up to 30% compared to other medications.
Hypertension’s Role in Dementia
Medical professionals have long recognized the link between high blood pressure and dementia. Maintaining cardiovascular health is crucial for brain health, and it follows that managing blood pressure could lower dementia risk. However, researchers from Amsterdam have discovered that specific antihypertensive medications may have additional protective effects on brain health beyond their primary function of regulating blood pressure.
Dr. Jakob Schroevers, the lead author of the study, noted, “Elevated blood pressure damages blood vessels, including those in the brain, leading to oxygen deprivation and subsequent brain tissue damage, which may contribute to various forms of dementia, including Alzheimer’s disease. Treating elevated blood pressure has been shown to lower dementia risk, with some types of blood pressure-lowering medications potentially reducing this risk more effectively than others.”
Identifying Effective Medications
A critical question arose regarding whether the type of antihypertensive medication matters in reducing dementia risk. A comprehensive study was necessary to determine if certain medications were more effective than others. Schroevers and his colleagues at Amsterdam UMC analyzed anonymized medical records from over 130,000 individuals in the Netherlands. Previous studies had established a correlation between blood pressure management and reduced dementia incidence, but small sample sizes and limited timeframes had obscured the findings.
Schroevers explained, “We had access to a very large population of community-dwelling individuals, enabling us to detect even subtle differences in risk and draw conclusions applicable to a wider audience.” The extensive patient data allowed the team to observe how different types of blood pressure medications affected dementia risk over time.
National Study Methodology
The nationwide cohort study involved examining anonymized medical records of patients prescribed antihypertensive drugs. Researchers collected comprehensive data on each case while considering factors such as sex, age, history of heart attacks, strokes, diabetes, and congestive heart failure, all of which could influence dementia risk. The large sample size enabled them to assess the impact of these confounding variables effectively.
The study also accounted for mortality rates, addressing concerns that patients using antihypertensives might appear less likely to develop dementia due to earlier mortality. Additionally, the researchers tracked changes in medication prescriptions over time.
Key Findings
Upon analyzing the data, researchers compared outcomes for patients using various antihypertensive medications. They found that continued use of any antihypertensive medication delayed the onset of dementia compared to those who discontinued their treatment. Specifically, angiotensin II receptor blockers, calcium channel blockers, beta-blockers, and thiazide diuretics all demonstrated a reduced dementia risk compared to angiotensin-converting enzyme (ACE) inhibitors.
Schroevers indicated, “Our findings align with previous studies that identified differences between types of BP-lowering medications. The consistent link between angiotensin receptor blockers (ARBs) and a lower dementia risk compared to ACE inhibitors is particularly noteworthy, as both medications are commonly prescribed to similar patient groups with high blood pressure.”
Implications for Prescribing Practices
Currently, ACE inhibitors are frequently prescribed for high blood pressure, especially for patients with prior strokes or heart attacks. This preference may stem from historical use rather than current evidence. The study suggests that switching from ACE inhibitors to alternatives could be a straightforward way to mitigate dementia risk.
Interestingly, the study revealed that ACE inhibitors had a significantly smaller impact on dementia risk compared to other antihypertensive medications. Researchers speculate that calcium channel blockers and angiotensin receptor blockers may also contribute to neuronal health beyond their vascular benefits.
The Need for Future Research
While these findings are promising, it is premature to discontinue ACE inhibitors in favor of beta-blockers or other alternatives. A randomized controlled trial is necessary to directly evaluate the anti-dementia effects of different antihypertensive medications. Given the complexities involved, a clearer understanding of these medications’ impacts is essential.
Schroevers emphasized, “Blood pressure-lowering drugs reduce dementia risk in patients with elevated blood pressure, with some types potentially being more effective than others. However, further research is needed to confirm these differences before treatment guidelines may be revised. Meanwhile, adopting a healthy lifestyle, including a balanced diet and effective blood pressure management, can empower individuals to lower their risk of dementia and other diseases.”
Conclusion
The study underscores the importance of ongoing research into blood pressure medications and their effects on brain health. For individuals concerned about dementia, consulting with healthcare providers about optimal medication regimens may be beneficial.
Many thanks to Dr. JL Schroevers for his insights. For further discussion, my Q&A with Dr. Schroevers is available here.
Schroevers JL, Hoevenaar-Blom MP, Busschers WB, et al. Antihypertensive medication classes and risk of incident dementia in primary care patients: a longitudinal cohort study in the Netherlands. The Lancet Regional Health – Europe. 2024;42. doi:10.1016/j.lanepe.2024.100927.